Trials / Completed
CompletedNCT02669758
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 281 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 3831 | Tablets were administered for daily dosing |
Timeline
- Start date
- 2016-01-20
- Primary completion
- 2018-06-29
- Completion
- 2018-06-29
- First posted
- 2016-02-01
- Last updated
- 2019-07-26
- Results posted
- 2019-07-09
Locations
31 sites across 4 countries: United States, Bulgaria, Serbia, Ukraine
Source: ClinicalTrials.gov record NCT02669758. Inclusion in this directory is not an endorsement.